A post-analysis of the SAVOR-TIMI 53 trial and a review of 17 different observational studies showed metformin use is associated with decreased all-cause mortality in people with type 2 diabetes and a high risk of cardiovascular events.
In a previous systematic review of 17 observational studies published in the Annals of Internal Medicine in 2017, researchers concluded that metformin use is associated with decreased all-cause mortality in patients with CKD, congestive heart failure, or chronic liver disease with hepatic impairment.
Find out more details about the Harvard Medical School study here.
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!
April 14, 2021 – April 16, 2021
August 5 11:30 am – 1:00 pm
August 6 11:30 am – 12:45 pm
August 26 11:30 am – 1:00 pm
September 2 11:30 am – 1:00 pm
September 20 11:30 am – 1:00 pm